|
Mutation Information
|
Mutation Site
|
K219E |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
NRTIs |
|
Country
|
Africa |
Literature Information
|
PubMed PMID
|
30513108
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
PLoS medicine |
|
Title
|
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial. |
|
Author
|
Kityo C,Szubert AJ,Siika A,Heyderman R,Bwakura-Dangarembizi M,Lugemwa A,Mwaringa S,Griffiths A,Nkanya I,Kabahenda S,Wachira S,Musoro G,Rajapakse C,Etyang T,Abach J,Spyer MJ,Wavamunno P,Nyondo-Mipando L,Chidziva E,Nathoo K,Klein N,Hakim J,Gibb DM,Walker AS,Pett SL,REALITY trial team. |
|
Evidence
|
The NRTI mutation K219E/Q (p = 0.004) and the NNRTI mutations K101E/P (p = 0.03) and P225H (p = 0.007) were less common in raltegravir-intensified ART, with no evidence of differences for other mutations (p > 0.1, S8 Fig).
|
|
|
HIV Mutation Detail Information